Biochemical characterization and experimental tumor targeting properties of an anti-CEA antibody fragment produced in E. Coli

Minerva Biotecnologica

Volumn 20, Issue 3, 2008, Pages 103-115

  Pérez Sánchez, Lincidio ^a   Pimentel, G ^b   Ravelo, R ^b   Ayala, M ^a   Bell, H ^a   Miranda, M ^b   Martinez Y R ^a   Sanchez I ^b   Musacchio, A ^a   Morera, V ^a   Canaan L ^a   Oliva, J P ^b   Gavilondo, J V ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

Author keywords

Carcinoembryonic antigen; Escherichia coli; Immunoglobulin fragments

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN SINGLE CHAIN FV FRAGMENT; IODINE 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BIOCHEMISTRY; BIOTECHNOLOGICAL PRODUCTION; CONTROLLED STUDY; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNOGLOBULIN STRUCTURE; IODINE 131 UPTAKE TEST; ISOTOPE LABELING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN TARGETING; TUMOR CELL;

ESCHERICHIA COLI; MUS MUSCULUS;

EID: 55049130824     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Oyen WJG, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M et al. Targeted therapy in nuclear medicine-cuffent status and future prospects. Ann Oncol 2007;18:1782-92.
2. Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, Ghosh R et al. Antigenic sites in carcinoembryonic antigen. Cancer Res 1989;49:4852-58.
3. Goldenberg DM. Cancer imaging with CEA antibodies: historical and current perspectives. Int J Biol Markers 1992;7:183-8.
4. Shulda GS and Krag DN. Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opin Biol Ther 2006;6:39-54.
5. Wong JYC, Chu DZ, Yamaguchi DM, Williams LE, Liu An, Wilczynski S et al. A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CFA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies. Clin Cancer Res 2000;6:3855-63.
6. Wong JYC, Shibata S, Williams LE, Kwok CS, Liu An, Chu DZ et al. A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52.
7. Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ilde DN, Kwok CS et al. Pilot Trial Evaluating an 1231-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer. Clin Cancer Res 2004;10:5014-21.
8. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimmers. Immunotechnology 1996;2:21-36.
9. Wu AM, Williams LE, Zieran L, Padma A, Sherman H, Bebb GG et al. Anticarcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 1999;4:47-54.
10. Olafsen T, Cheung Cw, Yasaki PJ, Li L, Sundaresan G, Gambhir SS et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17: 21-7.
11. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711-9.
12. Tormo BR, Gavilondo X Dominguez C, Freyre M, Rodriguez T, Biberfeld P. CEA in colonic adenocarcinomas and precancerous lesions. An immunohistochemical study with a novel monoclonal antibody. APMIS 1989;97:1073-80.
13. Pimentel G, Oliva J, Peralta R, Gonzáles A and Sánchez J. Pharmacokinetics of the Anti-CEA Monoclonal Antibody: Tc-99m iorCEA.1. World J Nucl Med 2004;3:119-24.
14. Perez L, Ayala M, Pimentel G, Bell H, Canáan Haden L, Bequet M et al. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen Biotechnol Appl Biochem 2006;43:39-48.
15. Holliger P, Prospero T and Winter G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd edition. New York: Cold Spring Harbor Laboratory Press: Cold Spring Harbor; 1989.
17. McEntire J. Selection and validation of analytical techniques. Biopharm. 1994;7:68-80.
18. Ferre-d'Amare AR and Burley SK. Use of dynamic light scattering to assess crystallizability of macromolecules and macromolecular assemblies. Structure 1994;2:357-9.
19. Olfert ED, Cross BM and McWilliam AA. Canadian Council on Animal Care. Guide for the care and use of experimental animals. Vol 1. 2nd edition. Toronto; 1993.
20. Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ. ScFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 1999;12:597-604.
21. Dolezal O, Pearce LA, Lawrence LJ, McCoy AJ, Hudson PJ and Kortt AA. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain FV fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimeros. Protein Eng. 2000;13:565-74.
22. Kortt AA, Dolezal O, Power BE, Hudson PJ. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomolecular Engineering 2001;18:95-108.
23. Power BE, Doughty L, Shapira DR, Burns JE, Bayly AM, Caine JM et al. Noncovalent scFv multimers of tumor-targeting anti-Lewisy hu3S193 humanized antibody. Protein Science 2003;12:734-47.
24. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999;293:41-56.
25. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 1999;453:164-8.
26. Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM. Immunosuppressive properties of anti-CD3 single-chain Fv and dia-body. J Immunol Methods 2004;285:111-27.
27. Wetlaufer DB. Adv Protein Chem 1962;17:303-91.
28. Bailey JE. In: Sober HA, editor. Handbook of biochemistry. Cleveland, Ohio: Chemical Rubber Co.; 1968. p. B-18.
29. Yanari S, Bovey FA. Interpretation of the ultraviolet spectral changes of proteins. J Biol Chem 1960;235:2818-26.
30. Brandts JF, Kaplan LJ. Derivative sspectroscopy applied to tyrosyl chromophores. Studies on ribonuclease, lima bean inhibitors, insulin, and pancreatic trypsin inhibitor. Biochemistry 1973;12:2011-24.
31. Lesser GJ, Rose GD. Hydrophobicity of amino acid subgroups in proteins. Proteins Struct Funct Genet 1990;8:6-13.
32. Carmichael JA, Power BE, Garrett TPJ, Yazaki M, Shively JE, Raubischek AA et al. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J Mol Biol 2003;326:341-51.
33. Berne BJ and Pecora R. Dynamic light scattering: with applications to chemistry, biology, and physics. New York: John Willey & Sons Inc; 1976.
34. Wyatt PJ. Light scattering and the absolute characterization of macromolecules. Anal Chim Acta 1993;272:1-40.
35. Ahrera K, Buchacherb A, Ibererb G, Josicb D, Jungbauer A. J Chromatogr A 2003;1009:89-96.
36. Desplancq D, King DJ, Lawson ADG, Mountain A. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng 1994;7:1027-33.
37. Arndt KM, Müller KM, and Plückthun A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 1998;3:12918-26.
38. Huang B-C, Foote LJ, Lankford TK, Davern SM, McKeown CK, Kennel SJ. A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting. Biochem Biophys Res Commun 2005;327:999-1005.
39. Lee YC, Boehm MK, Chester KA, Begent RHJ, Perkins SJ. J Mol Biol 2002;320:107-2.
40. Zimmermann R. In: Nuclear medicine. Radioactivity for diagnosis and therapy. EDP Sciences, ISBN 978-2-86883-962-6, 2006. p. 148-51.
41. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C et al. Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With 1311-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results. J Clin Oncol 2005,23:6763-70.
42. Olafsen T, Tan GJ, Cheung Cw, Yazaki PJ, Park JM, Shively JE et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315-23.
43. Liu S, Edwards S. Stabilization of (90)Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjugate Chem 2001;12:554-8.
44. Jain M, Batra SK. genetically engineered antibody fragments and PET imaging: a new era of radioimmunodiagnosis. J Nucl Med 2003;44:1070-1.